Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors - Wikidata - awgldk - TriplyDB

Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors

Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors

http://www.wikidata.org/entity/Q33402040

about

Epigenetic treatment of solid tumours: a review of clinical trials Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo Cyclin A1 modulates the expression of vascular endothelial growth factor and promotes hormone-dependent growth and angiogenesis of breast cancer.Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.Marine-derived angiogenesis inhibitors for cancer therapy.Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies Everolimus in colorectal cancer.Understanding and targeting resistance to anti-angiogenic therapies.Panobinostat: first global approval.Cancer epigenetics: new therapies and new challenges.Improved efficacy of therapeutic vaccination with viable human umbilical vein endothelial cells against murine melanoma by introduction of OK432 as adjuvant.Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP).

P2860

Q26773803-A4CE2EAE-C82E-4D22-BA2F-68C603F59F83 Q28485252-B07E5822-1A7C-44E6-A104-D97E68ADC866 Q31132489-5DCD910E-5A62-48EA-AB3B-06C03722439E Q33921891-7A46BCF1-23D0-4C14-8537-B470318DD6D8 Q36994177-6CD58550-2E5E-4952-85CC-228E3E5FEA29 Q37226511-52D9E53B-CA8C-4006-81B8-AC917B415A3C Q38081233-288ED663-72AA-4F91-B182-2ECF40D3A8CB Q38133568-AFB1D64C-2D2F-4938-8DC7-EA4B50293B14 Q38403118-C6655B03-0E0D-4ED8-86C7-7E0C65B1C795 Q43226742-BEA73DC4-50D8-4E05-B11F-F1115BAD8568 Q45055095-665F6FAD-5AE8-45F0-A47B-8A90026932FF Q45873478-446D5590-DDC6-4E57-89AB-1A47129D7DCC

P2860

Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors

http://www.wikidata.org/entity/Q33402040

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Phase I study of bevacizumab, ...... -589) in advanced solid tumors

@ast

Phase I study of bevacizumab, ...... -589) in advanced solid tumors

@en

type

label

Phase I study of bevacizumab, ...... -589) in advanced solid tumors

@ast

Phase I study of bevacizumab, ...... -589) in advanced solid tumors

@en

prefLabel

Phase I study of bevacizumab, ...... -589) in advanced solid tumors

@ast

Phase I study of bevacizumab, ...... -589) in advanced solid tumors

@en

P1433

Q33402040-8765B4E4-E2DD-4B21-B141-A50D6C487F51

P1476

Q33402040-EC394B73-3B47-4324-AD8E-AB7B8AA86EA0

P2093

Q33402040-07F225AE-F0A1-4D5F-BD7D-B08872D33831

Q33402040-2004B850-4F30-46D9-9B00-A3D7E620DD3C

Q33402040-3B851C59-335D-4043-B1FA-C51A53D11777

Q33402040-549DBF9C-994A-42DF-A8FB-504C74C7E69B

Q33402040-5A5AA947-ABC7-4156-B036-DEB71CA13EAE

Q33402040-62C27018-C349-458C-A3E3-618DE4EAA076

Q33402040-7F9C6D01-B391-46C2-8301-A724AFE1186A

Q33402040-CBD88979-5700-4056-927A-3E33063D553F

Q33402040-E03E3EB8-C7CD-405B-B8D6-610B15181193

Q33402040-F5DA690E-C270-42B2-9520-E8193F0217BD

P2860

Q33402040-07669D29-8A17-46AC-91AF-DFA603392004

Q33402040-134152BA-A1FC-4D6C-A999-7EB2F6962822

Q33402040-146F276B-A56F-4354-8FBC-3959B0AD9F07

Q33402040-197DACF2-1E53-47E1-891D-4ACCF64072CF

Q33402040-3635B9A1-2FBA-44D2-A8C5-21D8019C6011

Q33402040-3E44C40F-5F46-42C8-8FA6-0083622EDA9B

Q33402040-3F7406C7-2982-4850-B6F0-FD5A46C3B179

Q33402040-469C04EB-F598-466D-979B-E15D6B22F0C1

Q33402040-49B63ABE-56A3-435D-B6AA-6ACC7F8B4E9D

Q33402040-4D7C2FA7-4C3A-4EFF-AEE0-7F26AD4EC91C

P2888

Q33402040-98ABC7E8-EFB7-4519-9E8E-F9FCD1EA38E1

P304

Q33402040-00F7D400-D40B-4AA8-B56C-6BD3B054A297

P31

Q33402040-9BF9420F-0697-4913-B118-56B0F109DC73

P356

Q33402040-914B0E12-B700-488A-B864-4CB31F4CE123

P433

Q33402040-30A08C77-98B4-4E00-A4E0-3D56C1313E18

P478

Q33402040-B8CAD37E-23C6-42F4-A1E8-B6AA501AE188

P50

Q33402040-BD7C4523-682C-4BD1-9765-4AC52619102D

Q33402040-FA840DD3-4EF2-4D64-9170-D93F9A479BEB

P577

Q33402040-49F36CD9-16FC-417B-B2AA-441C2E00B961

P5875

Q33402040-3B4046C3-0327-4A37-8E48-EB07AFE84598

P6179

Q33402040-8135F19C-67FB-48B8-A9E0-9E196E4B870A

P698

Q33402040-41030A2F-A74E-45AB-902F-E1590DBA04BA

P921

Q33402040-73077777-5EA5-46B0-881B-8A0522195B96

P932

Q33402040-404EF783-B7B5-435A-9A5A-3E7AF733930F

P356

S00280-012-1911-1

P1433

Cancer Chemotherapy and Pharmacology

P1476

Phase I study of bevacizumab, ...... -589) in advanced solid tumors

@en

P2093

Alexander N Starodub

http://www.w3.org/2001/XMLSchema#string

Andrew B Nixon

http://www.w3.org/2001/XMLSchema#string

Andrew Dellinger

http://www.w3.org/2001/XMLSchema#string

Herbert I Hurwitz

http://www.w3.org/2001/XMLSchema#string

Hope E Uronis

http://www.w3.org/2001/XMLSchema#string

Jingquan Jia

http://www.w3.org/2001/XMLSchema#string

Kellen L Meadows

http://www.w3.org/2001/XMLSchema#string

Michael A Morse

http://www.w3.org/2001/XMLSchema#string

P Kelly Marcom

http://www.w3.org/2001/XMLSchema#string

Sherri T Haley

http://www.w3.org/2001/XMLSchema#string

P2860

Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

Modes of resistance to anti-angiogenic therapy

Targeting HIF-1 for cancer therapy

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases

Evaluation of HIF-1 inhibitors as anticancer agents

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

P2888

s00280-012-1911-1

P304

251-258

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-012-1911-1

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

S. Yousuf Zafar

John H Strickler

P577

2012-06-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228088282

http://www.w3.org/2001/XMLSchema#string

P6179

1011070767

http://www.w3.org/2001/XMLSchema#string

P698

22744359

http://www.w3.org/2001/XMLSchema#string

P921

P932

3793400

http://www.w3.org/2001/XMLSchema#string